Please assess the completion status of the following clinical trial:

Trial Title: 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Psoriatic Arthritis (PsA) classified by ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria.~* Rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies negative.~* Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis.~* Inadequate control of symptoms with NSAID.~Exclusion Criteria:~* Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process.~* Subjects taking high potency opioid analgesics.~* Previous exposure to secukinumab or other biologic drug directly targeting interleukin-17 (IL-17) or IL-17 receptor.~* Ongoing use of prohibited psoriasis treatments / medications.~* Subjects who have ever received biologic immunomodulating agents except for those targeting TNFα.~* Previous treatment with any cell-depleting therapies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (AIN457) 150 mg s.c. (Type: EXPERIMENTAL): 1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
- Secukinumab (AIN457) 300 mg s.c. (Type: EXPERIMENTAL): 2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).